Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

The COVID-19 variants first detected in the U.K. and South Africa and now circulating globally aren't a current threat to the effectiveness of the first vaccines, but mutations will be closely monitored because "they could be an issue," NIAID director Anthony Fauci tells Axios.

The big picture: Vaccinations are underway, albeit with a slow start. The get-back-to-normal-goal depends on reaching 70%–85% herd immunity in the population, Fauci says. While there are some concerns the mutations might circumvent the vaccines, he says they pose more of a problem for certain treatments than for vaccines.

What's happening: Viruses mutate frequently, but often those changes are small and don't cause issues with treatments or vaccines. Public health officials have been tracking SARS-CoV-2 variants closely.

B.1.1.7 doesn't appear to be more virulent or to obviate the effect of the vaccine, based on what British doctors are saying, Fauci says.

  • B.1.1.7 is more transmissible because it binds more readily to the ACE2 receptor, which is how the virus enters cells.
  • That pushes the need for faster vaccinations, says Carlos del Rio, distinguished professor of medicine at Emory University School of Medicine.
  • "If the R-naught goes from 2.5 to 2.9 in a totally naive population, after 10 cycles of transmission, instead of 9,000 people infected, you have 42,000 people infected," del Rio warns.

The 501.V2 variant is "a little bit more concerning regarding the possibility of interfering with some of the monoclonal antibodies," based on preliminary findings, Fauci says.

  • Monoclonal antibody treatments precisely target one specific region of the virus and "if the mutation happens to be at that epitope, that could obviate the effect" of the treatment, he says.
  • Vaccines, on the other hand, "induce a polyclonal response against multiple different aspects of the spike protein," Fauci points out. "For something to really circumvent the efficacy of the vaccine, it's got to have a lot of mutations that are all at the right places."

What they're watching: Scientists are following the strains and testing them against the vaccines.

  • "If it doesn't impact the vaccine, you're good to go. If it does, you have to make some minor modifications of the vaccine to be able to circumvent the changes that occur in the mutations," Fauci says.
  • With the "plug-and-play" nature of the mRNA vaccines, it is much easier to alter the makeup of those vaccines, he adds.
  • And because there's now a large amount of data about the mRNA-based vaccine platform, "it is likely the FDA would consider it merely a strain change, which doesn't require starting from square one," he says.

The bottom line: "You always have to take these things seriously, follow them closely, and hope there will not be a problem. But, if there is, you have to adjust to it," Fauci says. "And now we have the technology to do that pretty easily."

Go deeper

Jan 30, 2021 - World

Science helps New Zealand avoid another coronavirus lockdown

New Zealand Prime Minister Jacinda Ardern (L) visits a lab at Auckland University in December. Photo: Phil Walter/Getty Images

New Zealand has avoided locking down for a second time over COVID-19 community cases because of a swift, science-led response.

Why it matters: The Health Ministry said in an email to Axios Friday there's "no evidence of community transmission" despite three people testing positive after leaving managed hotel isolation. That means Kiwis can continue to visit bars, restaurants and events as much of the world remains on lockdown.

Scoop: Leaked Ukraine memo reveals scope of Russia's aggression

Russian President Vladimir Putin visits a military exposition in Sevastopol, Crimea, in Jan. 2020. Photo: Mikhail Svetlov/Getty Images

Russia has been holding last-minute military exercises near commercial shipping lanes in the Black Sea that threaten to strangle Ukraine's economy, according to an internal document from Ukraine's ministry of defense reviewed by Axios.

Why it matters: With the eyes of the world on the massive buildup of troops in eastern Ukraine, the leaked memo shows Russian forces escalating their presence on all sides of the Ukrainian border.